New Delhi: A vaccine candidate developed at the University of Oxford has shown encouraging results in early human testing and appears to be “safe well-tolerated, and immunogenic”, according to a study published in The Lancet.
Trials involving 1,077 people showed the injection led to them making antibodies and white blood cells that can fight coronavirus.
“Our preliminary findings show that the candidate ChAdOx1 nCoV-19 vaccine given as a single dose was safe and tolerated, despite a higher reactogenicity profile than the control vaccine, MenACWY,” the researchers, led by Pedro M Folegatti and Katiet Ewer, wrote in the study.
Results of phase 1/2 Oxford Covid-19 Vaccine trial published. Editor in Chief of UK based medical Journal ‘The Lancet’ says it is “safe, well-tolerated and immunogenic.” pic.twitter.com/8SyI97Dqgb
— ANI (@ANI) July 20, 2020
“No serious adverse reactions to ChAdOx1 nCoV-19 occurred. The majority of adverse events reported were mild or moderate in severity, and all were self-limiting,” the study said. The clinical trials of a potential COVID-19 vaccine on humans began in April. The Oxford vaccine — called ChAdOx1 nCoV-19 — is made from a harmless chimpanzee virus.
The human vaccine trial has been developed by scientists at Oxford University’s Jenner Institute, the university confirmed to CNN. (ANI)
